Inhibition of Glucagon-Induced Hyperglycemia Predicts Glucose Lowering Efficacy of a Glucagon Receptor Antagonist, MK-0893, in Type 2 Diabetes (T2DM)

被引：0

|

作者：

Ruddy, Marcella

Pramanik, Barnali

Lunceford, Jared

Li, Susie

Cilissen, Caroline

Stoch, S. Aubrey

Wagner, John

Amatruda, John

Herman, Gary

Kaufman, Keith

机构：

来源：

DIABETES | 2011年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

311-OR

引用

收藏

页码：A85 / A86

页数：2

相关论文

共 50 条

[1] Efficacy and Tolerability of MK-0893, a Glucagon Receptor Antagonist (GRA), in Patients with Type 2 Diabetes (T2DM)
Engel, Samuel S.
Xu, Lei
Andryuk, Paula J.
Davies, Michael J.
Amatruda, John
Kaufman, Keith
Goldstein, Barry J.
[J]. DIABETES, 2011, 60 : A85 - A85
[2] Discovery of MK-0893: A glucagon receptor antagonist for the treatment of type II diabetes
Parmee, Emma R.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[3] Efficacy and safety of the glucagon receptor antagonist, MK-0893, in combination with metformin or sitagliptin in patients with type 2 diabetes mellitus
Engel, S. S.
Teng, R.
Edwards, R. J.
Davies, M. J.
Kaufman, K. D.
Goldstein, B. J.
[J]. DIABETOLOGIA, 2011, 54 : S86 - S87
[4] Recovery from Hypoglycemic Clamp in Type 2 Diabetes (T2DM) Patients during β-Adrenergic Blockade Plus Glucagon Receptor Blockade with MK-0893
Troyer, Matthew D.
Hompesch, Marcus
Jax, Thomas
Pramanik, Barnali
Liu, Fang
Morrow, Linda
Win, Khin
Reynders, Tom
Liu, Chengcheng
Engel, Samuel
Heise, Tim
Maliwat, Elsa
Denney, William S.
Kelley, David E.
Wagner, John A.
Stoch, S. Aubrey
[J]. DIABETES, 2011, 60 : A137 - A137
[5] Single Doses of the Glucagon Receptor Antagonist LY2409021 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2DM)
Kelly, Ronan P.
Abu-Raddad, Eyas J.
Tham, Lai San
Fu, Haoda
Pinaire, Jane A.
Deeg, Mark A.
[J]. DIABETES, 2011, 60 : A275 - A275
[6] Contribution of glucagon suppression to improved postprandial hyperglycemia induced by exenatide in patients with T2DM
Wajcberg, Estela
Triplitt, Curtis
Sriwijitkamol, Api
Defronzo, Ralph A.
Cersosimo, Eugenio
[J]. DIABETES, 2006, 55 : A28 - A28
[7] Assessment of PF-06291874 (PF), a Glucagon Receptor Antagonist Administered as Monotherapy for Four Weeks in Patients with Type 2 Diabetes Mellitus (T2DM)
Bergman, Arthur
Tan, Beesan
Somayaji, Veena
Calle, Roberto A.
Kazierad, David J.
[J]. DIABETES, 2016, 65 : A283 - A283
[8] Efficacy and Safety of PF-06291874 (PF), a Glucagon Receptor Antagonist Administered for 12 Weeks to Patients with Type 2 Diabetes Mellitus (T2DM) on Background Metformin Therapy
Calle, Roberto A.
Bergman, Arthur
Somayaji, Veena
Chidsey, Kristin
Kazierad, David J.
[J]. DIABETES, 2017, 66 : A327 - A327
[9] Blood Glucose Lowering Effects of Dextromethorphan in People with Type 2 Diabetes Mellitus (T2DM)
Stirban, Alin
Marquard, Jan
Wnendt, Stephan
Herebian, Diran
Schliess, Freimut
Heise, Tim
Lammert, Eckhard
[J]. DIABETES, 2014, 63 : A275 - A275
[10] Glucagon Receptor Antagonist LY2409021 Does Not Impede Recovery From Insulin Induced Hypoglycemia in Patients With T2DM
Kelly, Ronan P.
Lim, Chay Ngee
Pratt, Edward
Loh, Mei Teng
Deeg, Mark
Fu, Haoda
Cui, Sherry
Garhyan, Parag
[J]. DIABETES, 2012, 61 : A256 - A256

← 1 2 3 4 5 →